Drug Profile
SR T100
Alternative Names: SR-T100Latest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator G&E Herbal Biotechnology
- Class Antineoplastics; Phytotherapies
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Actinic keratosis
- Phase II Condylomata acuminata
- No development reported Vulvar intraepithelial neoplasia
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for phase-0 development in Vulvar-intraepithelial-neoplasia in Taiwan (Topical, Gel)
- 28 Oct 2019 No recent reports of development identified for phase-I development in Actinic keratosis in Taiwan (Topical, Gel)
- 15 Jul 2019 G&E Herbal Biotechnology suspends a phase II trial in Warts in Taiwan, due to budget issue (NCT01796795)